Xiao-Hui Liu

This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Supergen, Inc, Astex Pharmaceuticals, Inc., Tolero Pharmaceuticals, Inc.. Active years: 2010-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiao-Hui Liu. Retrieved from https://idiyas.com/inventor/xiao-hui-liu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 2)

% Patents Active = 50.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 88(Granted Patents)

Location History:

Sandy, UT (US) (2010 - 2013)
Holladay, UT (US) (2014)

Company Filing History:

Astex Pharmaceuticals, Inc.

patents

1 out of 21

Tolero Pharmaceuticals, Inc.

patents

Years Active: 2010-2014

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8710057 - Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitors (2014-04-29),

2. 8445502 - Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same (2013-05-21),

3. 7820684 - Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same (2010-10-26),

4. 7750007 - Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors (2010-07-06),

Title: Innovations and Contributions of Inventor Xiao-Hui Liu

Introduction

Xiao-Hui Liu is a notable inventor based in Sandy, UT (US). She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of protein kinase inhibitors. With a total of 4 patents to her name, her work has implications for cancer treatment and other related conditions.

Latest Patents

Among her latest patents is the invention of imidazo[1,2-B]pyridazine and pyrazolo[1,5-A]pyrimidine derivatives, which serve as protein kinase inhibitors. This invention provides compounds that can be utilized in the treatment of cancer and other Pim kinase-associated conditions. Another significant patent involves pharmaceutical formulations comprising the protein kinase inhibitor MP470, which is aimed at treating conditions characterized by undesirable cell proliferation, such as cancer.

Career Highlights

Xiao-Hui Liu has worked with several prominent companies in the pharmaceutical industry, including Supergen, Inc. and Tolero Pharmaceuticals, Inc. Her expertise in the field has allowed her to contribute to innovative solutions in cancer treatment.

Collaborations

Throughout her career, she has collaborated with notable professionals such as David J Bearss and Hariprasad Vankayalapati. These collaborations have further enhanced her research and development efforts in the pharmaceutical domain.

Conclusion

Xiao-Hui Liu's contributions to the field of pharmaceutical sciences through her patents and collaborations highlight her role as an influential inventor. Her work continues to pave the way for advancements in cancer treatment and related therapies.

Profile summary based on public USPTO records.